1. FBLN4 as candidate gene associated with long-term and short-term survival with primary glioblastoma
- Author
-
Zhenju Li, Kewei Zhang, Yiping Li, Hongyan Yuan, Fubin Li, Songtian Che, Jinxiang Liu, Ping He, Li Bie, Yujia Liu, Honghua Lu, and Ye Li
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Candidate gene ,Microarray analysis techniques ,business.industry ,medicine.disease ,CHI3L1 ,law.invention ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Downregulation and upregulation ,law ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Pharmacology (medical) ,business ,Gene ,Polymerase chain reaction ,Glioblastoma ,Tumor marker - Abstract
BACKGROUND Glioblastoma multiforme (GBM) is the most common malignant and lethal type of primary central nervous system tumor in humans. In spite of its high lethality, a small percentage of patients have a relatively good prognosis, with median survival times of 36 months or longer. The identification of clinical subsets of GBM associated with distinct molecular genetic profiles has made it possible to design therapies tailored to treat individual patients. METHODS We compared microarray data sets from long-term survivors (LTSs) and short-term survivors (STSs) to screen for prognostic biomarkers in GBM patients using the WebArrayDB platform. We focused on FBLN4, IGFBP-2, and CHI3L1, all members of a group of 10 of the most promising, differentially regulated gene candidates. Using formalin-fixed paraffin-embedded GBM samples, we corroborated the relationship between these genes and patient outcomes using methylation-specific polymerase chain reaction (PCR) for MGMT methylation status and quantitative reverse transcription PCR for expression of these genes. RESULTS Expression levels of the mRNAs of these 3 genes were higher in the GBM samples than in normal brain samples and these 3 genes were significantly upregulated in STSs compared to the levels in LTS samples (P
- Published
- 2017